Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 12, Number 3—March 2006

Cost-effectiveness of West Nile Virus Vaccination

Armineh Zohrabian*Comments to Author , Edward B. Hayes†, and Lyle R. Petersen†
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †Centers for Disease Control and Prevention, Fort Collins, Colorado, USA

Main Article

Table 1

Uniform distributions for each variable used in simulations to assess the cost-effectiveness of vaccination against West Nile virus (WNV)*

Variable Lower limit Baseline Upper limit
Probability of infection 0.012 0.016 0.02
Probability of symptomatic illness 0.15 0.20 0.25
Probability of symptomatic illness after vaccination† 0.03 0.04 0.05
Probability of neuroinvasive disease, given symptoms 0.027 0.036 0.045
Probability of death, given neuroinvasive disease 0.07 0.09 0.11
Probability of disability, given neuroinvasive disease 0.26 0.35 0.44
Cost of neuroinvasive disease $20,625 $27,500 $34,375
Cost of death (direct and indirect financial losses) $150,000 $200,000 $250,000
Cost of lifelong disability $158,000 $210,000 $263,000
Cost of uncomplicated WNV febrile illness $750 $1,000 $1,250
Cost of vaccination $75 $100 $125

*Upper and lower limits are calculated as ±25% of the baseline values and rounded up.
†Baseline vaccine effectiveness is assumed to be 80%.

Main Article

Page created: January 27, 2012
Page updated: January 27, 2012
Page reviewed: January 27, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.